Sigilon Therapeutics Inc. (SGTX) News
Filter SGTX News Items
SGTX News Results
|Loading, please wait...|
Latest SGTX News From Around the Web
Below are the latest news stories about SIGILON THERAPEUTICS INC that investors may wish to consider to help them evaluate SGTX as an investment opportunity.
Regulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector.
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares.
We're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today!
BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data.
Eco Wave Power Global (WAVE) stock is on the rise Thursday with heavy trading despite a lack of news concerning the wave energy company.
Sigilon Therapeutics (SGTX) stock is rocketing higher on Thursday morning after Eli Lilly (LLY) agrees to acquire the company.
Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.
Eli Lilly (LLY) shares rose more than 1% on Thursday after announcing it will acquire Sigilon Therapeutics (SGTX) in an all-cash deal worth up to $309.6 million. Eli Lilly will pay $14.92 per share or $34.6 million, along with $111.64 per share to shareholders if the company achieves specified regulatory and developmental goals. According to the terms of the agreement, total compensation could jump to $125.56 per share or $309.6 million, if certain development, research, and regulatory goals are met.
Sigilon Therapeutics Inc (NASDAQ: SGTX) shares are skyrocketing after Eli Lilly And Co (NYSE: LLY) agreed to acquire the company for a purchase price of $14.92 per share in cash (an aggregate of approximately $34.6 million). Sigilon is also entitled to one non-tradeable contingent value right ("CVR") per share to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest (an aggregate of up to approximately $309.